GM1 gangliosidosis is a lysosomal storage disease (LSD) caused by β-galactosidase deficiency, characterized by the accumulation of gangliosides in various tissues. Among different GM1 forms (infantile form, late-infantile and juvenile form, and late-onset form), the infantile form is the most severe: despite an early clinical onset with rapid neurodegeneration, coarse face, abdominal visceromegaly and skeletal abnormalities, the diagnosis is usually delayed, given the lack of recognized early disease-specific markers. We report the case of a newborn presenting with mild edema of hands and feet, mild transient hypoalbuminemia and isolated hyperphosphatasemia at three weeks of life. The first cardiological evaluation showed mild mitral regurgitation. Despite the absence of neurological symptoms, organomegaly, or a coarse face, the turgid consistency of the limbs, together with mitral regurgitation and persistent hyperphosphatasemia, led to multiorgan investigations with discovery of bilateral cherry-red spots and a beak-shaped lumbar vertebra. The cardiological follow-up revealed a dysplastic mitral valve. In the suspicion of a lysosomal disease, biochemical investigations were planned. An altered profile of urinary oligosaccharides, along with low β-galactosidase activity in leukocytes, led to the diagnosis of infantile GM1 gangliosidosis at 3 months of age. The GLB1 gene analysis confirmed the diagnosis. Genetic testing for GLB1 should be considered in cases of persistent hyperphosphatemia, especially if it is associated with any other clinical indicator of GM1, such as limb edema.

Report of a case of central retinal artery occlusion after sphenopalatine artery (SPA) embolization. A review of the literature describing complications after SPA embolization and ligation. Retrospective case report and literature review. A 68-year-old woman with a history notable for hypertension, hyperlipidemia, and 8 years of intermittent right-sided epistaxis previously requiring blood transfusions underwent right-sided embolization of the SPA with the neurosurgery service. Sphenopalatine artery embolization was achieved with Embosphere microspheres and Concerto coils. No thromboembolic complications were noted at the conclusion of the case. On waking from general anesthesia, the patient reported painless right-sided vision loss and was found to have best-corrected visual acuity of light perception, a relative afferent pupillary defect, and a cherry-red spot with vascular attenuation consistent with central retinal artery occlusion. Central retinal artery occlusion can be a complication of ipsilateral SPA embolization.

Sialidosis, also known as Mucolipidosis Type I, is a rare condition caused by defects in the NEU1 gene which causes the accumulation of sialylated peptides, oligosaccharides, and glycoproteins leading to neurological decline. Haematopoetic stem cell transplantation has been performed in the symptomatic phase twice in the literature but has failed to prevent deterioration. We report on a case where a 4-year-old child was diagnosed with pre-symptomatic sialidosis due to investigation following the incidental detection of a cherry-red spot prior to the onset of neurological symptoms. We performed haematopoetic stem cell transplantation with a matched unrelated cord blood unit with optimal timing prior to clinical decline, achieving full donor engraftment with a largely uneventful post-transplant recovery followed by a period of relative clinical stability. However, subsequent neurological decline detailed by clinical history and radiological findings has occurred suggesting a lack of disease responsiveness to transplantation despite optimal timing. We go on to provide supporting laboratory investigations detailing sialidosis fibroblast culture as part of a novel cross-correction assay and compare results to other transplant responsive lysosomal storage disorders such as mucopolysaccharidosis type 1-H and detail a lack of cross-correction in concordance with our clinical findings. We conclude that conventional allogeneic haematopoetic stem cell transplantation is not a viable disease-modifying treatment option in sialidosis, even when performed optimally in the pre-symptomatic phase, and suggest that alternative treatment options must be explored to improve outcomes in this condition.

PurposeTo study the association between fundus changes and visual prognosis in central retinal artery occlusion (CRAO).MethodsA total of 222 CRAO cases hospitalized at Hebei Eye Hospital between January 2013 and December 2016 were included in this study. Fundus photographs on admission were evaluated via dual independent image review. Retinal ischemic edema and cilioretinal arteries were graded. Logistic regression analysis was performed to explore the association between fundus findings and visual prognosis in CRAO.ResultsThe main fundus changes in CRAO patients on admission included retinal ischemic edema (95.0%), cherry-red spot (89.6%), retinal arterial narrowing (65.3%) and venous narrowing (53.6%), cotton-wool spots (53.6%), optic disc margin blurring (36.0%) and pallor (35.1%), retinal venous dilation (21.2%), and retinal hemorrhages (12.6%). Upon admission, retinal edema grades were grade 0 in 11 eyes (5.0%), grade 1 in 23 (10.4%), grade 2 in 80 (36.0%); and grade 3 in 108 (48.6%). Forty-seven eyes (21.1%) showed fissure-like edema, while 164 eyes (73.9%) exhibited a diffuse pattern. Chi square test showed the grade and pattern of retinal ischemic edema, the border and size of the cherry-red spot, the presence of retinal hemorrhage and cotton wool spots, macular folds and retinal arterial narrowing were all significantly associated with the time from symptom onset to presentation. Multivariate logistic regression analysis identified visual acuity at presentation, retinal ischemic grade, optic disc margin clarity, cherry-red spot size, and the presence of a cilioretinal artery supplying the macula as predictive factors for visual prognosis in CRAO.ConclusionThe fundus changes in acute CRAO were correlated with the visual prognosis. Visual acuity at presentation, grade of retinal ischemic edema, clarity of the optic disc margin, size of the cherry-red spot, and the presence of a cilioretinal artery supplying the macula could be predictive factors for visual prognosis in CRAO.

Central Retinal Artery Occlusion (CRAO) is an ocular emergency that threatens vision when the central retinal artery, the retina's source of arterial blood, becomes occluded. The occlusion - most commonly caused by an embolus or thrombus - is the cause of sudden, painless, and profound monocular visual loss. CRAO has been described as a "stroke of the eye" due to its sudden nature and ischemic presentation. On fundoscopy, the retina appears pale with a typical cherry-red macula spot, and the condition betrays the underlying retinal infarction. The disease mandates immediate medical attention because the window for proper treatment is short and prognosis of visual recovery in most instances is poor.

Background. Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterized by an initial prodromal phase with eosinophil-driven manifestations such as asthma, nasal polyposis, and rhinitis, followed by an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitic phase. Ocular involvement is possible but uncommon (approximately 15% of cases), and central retinal artery occlusion (CRAO) represents an exceedingly rare event. Although benralizumab, a monoclonal antibody targeting the IL-5 receptor, has proven effective in managing eosinophilic manifestations such as asthma and nasal polyposis, its ability to prevent vasculitic damage remains uncertain. We report a case of EGPA complicated by bilateral CRAO occurring during benralizumab therapy. Case report. A 61-year-old man with a history of adult-onset chronic rhinosinusitis and severe asthma, treated with benralizumab since 2022, presented to the emergency department in June 2024 with sudden bilateral blindness preceded by transient amaurosis episodes, without systemic symptoms or ocular pain. Ophthalmologic examination revealed markedly reduced visual acuity in both eyes (hand motion only) and a relative afferent pupillary defect. Fundus examination showed pale optic discs with central cherry-red spots. Optical coherence tomography (OCT) demonstrated inner retinal layer edema and hyperreflectivity (Figure 1a–c), while fluorescein angiography confirmed delayed retinal arteriolar filling (Figure 1d), findings consistent with CRAO. Laboratory tests revealed elevated inflammatory markers and high-titer myeloperoxidase (MPO)-ANCA positivity (134 IU/mL; positive >3 IU/mL) in the absence of peripheral eosinophilia, likely due to benralizumab therapy. Based on clinical and serological findings, a diagnosis of EGPA was established. High-dose corticosteroids and combined rituximab–cyclophosphamide therapy were initiated according to KDIGO and PEXIVAS recommendations. After an initial improvement, disease relapse occurred with increased MPO-ANCA levels, requiring steroid escalation and two additional cyclophosphamide infusions (cumulative dose: 4 g). Within six months, inflammatory markers and antibody titers normalized; however, visual loss persisted with only partial recovery (finger counting at 1 meter OD, 2/10 OS). Maintenance therapy with rituximab 500 mg every six months was started. Conclusions. This is the first reported case of EGPA complicated by bilateral CRAO occurring during benralizumab treatment. Suppression of eosinophilia did not prevent the development of a severe ANCA-mediated complication, suggesting distinct pathogenic pathways for eosinophilic and vasculitic damage. This case highlights the limitations of IL-5R inhibition in preventing systemic vasculitis and underscores the importance of early and aggressive immunosuppression to avoid irreversible outcomes.

BackgroundAcid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B, is a rare autosomal recessive lysosomal storage disorder caused by SMPD1 mutations. It is characterized by sphingomyelin accumulation and a broad clinical spectrum ranging from severe neurodegeneration in type A to a milder visceral phenotype in type B. Intermediate forms (type A/B) show overlapping features of both subtypes.Case presentationWe report a 6-month-old boy with ASMD type A/B who first presented with meningoencephalitis and a single seizure most likely secondary to an intercurrent viral infection rather than a primary disease manifestation. Subsequent evaluation revealed multiple systemic red-flag features including marked hepatosplenomegaly, severe growth failure, a cherry-red spot, macroglossia, dysmorphic facial features, recurrent pneumonia, and bilateral sensorineural hearing loss. Laboratory investigations demonstrated elevated liver enzymes and cerebrospinal fluid abnormalities, while auditory brainstem response confirmed the hearing impairment. Enzyme assay confirmed reduced ASM activity, and targeted SMPD1 genetic sequencing identified a homozygous frameshift mutation classified as pathogenic according to ACMG criteria, establishing the diagnosis of an intermediate ASMD phenotype. ConclusionThis case highlights the diagnostic challenges posed by ASMD type A/B, particularly when the initial presentation mimics an acute infection. The overlap of coincidental infectious illness with systemic red-flag features, the clinical variability of intermediate phenotypes, and the rarity of the disorder all contribute to delayed recognition. These factors underscore the importance of maintaining a high index of suspicion and pursuing early metabolic and genetic testing in atypical pediatric presentations.Trial registrationNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40348-025-00206-z.

Lysosomal storage disorders, also known as lipidoses, encompass various inherited diseases resulting from the deficiency of specific lysosomal hydrolases. Tay–Sachs disease (TSD) is a rare genetic disorder predominantly seen in certain populations, including Ashkenazi Jews, French-Canadians, and Cajuns. Its prevalence in the general population, including in India, is much lower. There is limited specific data on the prevalence of TSD in the Indian population, but it is considered extremely rare compared with the high-risk groups mentioned. We report a case of a 10-month-old infant, the first infant of third-degree consanguineous parents, who had an uneventful birth history. The infant presented with delayed developmental milestones, macrocephaly, cherry-red spots in both eyes, and poor hair growth, but without organomegaly or seizures. Hexosaminidase A enzyme activity was found to be reduced. Genetic testing revealed a novel homozygous variation in the HEXA gene in the patient’s DNA sample.

Objectives: To report a rare pediatric case of spontaneous high-flow direct carotid–cavernous fistula (CCF) presenting with rapid, vision-threatening orbital congestion, and to highlight the diagnostic pathway and management barriers in a low-resource setting. Case Presentation: An 12-year-old boy presented with 3–4 weeks of progressive left-eye proptosis, orbital pain, and visual decline, culminating in no light perception. Examination showed marked left-sided proptosis, afferent pupillary defect, and elevated intraocular pressure (24–25 mmHg; right eye 12 mmHg). Funduscopy revealed dilated, tortuous retinal veins with venous pulsations, without cherry-red spot or disc edema. Orbital B-scan demonstrated a well-defined hypoechoic retrobulbar structure suggestive of vascular dilation. Brain-orbit MRI identified multiple T2 flow voids, a markedly dilated superior ophthalmic vein draining into the cavernous sinus and appearing connected to the left internal carotid artery, associated enlarged extraocular muscles, and retrobulbar edema—findings consistent with a high-flow direct CCF. Urgent digital subtraction angiography and endovascular embolization were recommended to prevent intracranial venous hypertension and irreversible optic neuropathy. Due to the absence of interventional neuroradiology services and endovascular equipment locally, the patient was referred abroad for definitive management, with close ophthalmic monitoring advised pending transfer. Conclusion: CCF, uncommon in children, should be considered in pediatric proptosis with visual decline—even without trauma. Imaging enables early recognition; however, timely access to endovascular therapy determines visual and neurological outcomes. This case underscores gaps in neurovascular care within low-resource settings and supports investment in endovascular capacity, clinician training, and referral networks to mitigate preventable vision loss in presentations.

Central retinal artery occlusion (CRAO) is an ophthalmic emergency characterized by sudden vision loss; it is rarely associated with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Herein, we report a case of a man in his 80s who, experiencing persistent fever, weight loss, and myalgia, received corticosteroid therapy at a local hospital for a presumptive diagnosis of polymyalgia rheumatica. While on this treatment, he suddenly developed vision loss in the left eye; visual acuity was limited to light perception, and fundus examination revealed a cherry-red spot in the macula, consistent with CRAO. The patient was urgently referred and admitted to the rheumatology department of our hospital for evaluation and management of suspected systemic vasculitis underlying CRAO. The presence of persistent fever, elevated inflammatory markers, positive myeloperoxidase-ANCA, interstitial lung disease, purpura, and small-vessel vasculitis confirmed via muscle biopsy led to the diagnosis of microscopic polyangiitis. Given this clinical course and definitive diagnosis, his initial systemic symptoms were considered early manifestations of the underlying microscopic polyangiitis. The patient was treated with methylprednisolone pulse therapy and rituximab, followed by azathioprine; the inflammatory markers improved, and visual acuity recovered to hand motion by discharge. This case highlights that when CRAO occurs alongside systemic symptoms, ANCA-associated vasculitis should be strongly considered as a potential underlying cause. Timely identification of such systemic vasculitis is crucial to enhance the possibility of visual recovery and to reduce complications affecting vital organs beyond the eye.

Cherry-red Spot in Tay-Sachs Disease.

Retinal artery occlusion (RAO) is a sight-threatening condition that requires prompt diagnosis to prevent irreversible vision loss. This study presents an innovative AI-driven approach for RAO detection from fundus images, marking the first application of deep learning for this purpose. Using a self-supervised learning (SSL) framework with SimCLR, our model addresses the challenge of limited labeled RAO data. The ResNet50 model pretrained with SimCLR demonstrated high diagnostic accuracy, achieving areas under the receiver operating characteristic curve (AUC) of 0.924 and 0.988 on two external validation datasets, highlighting its robustness and generalizability in RAO detection. To enhance transparency in clinical AI, we incorporated a multimodal interpretability approach using a ChatGPT-4-based AI chatbot. This chatbot, combined with Grad-CAM visualizations, provides detailed clinical explanations of the model's predictions, emphasizing key RAO features such as retinal whitening and cherry-red spots. This multimodal interpretability framework improves clinicians' understanding of the model's decision-making process, facilitating clinical adoption and trust. By automating RAO detection, this AI model serves as a valuable tool for the early identification of ocular and systemic vascular risks, enabling timely intervention. These findings highlight the potential of fundus imaging for RAO detection and broader cardiovascular risk assessment, advancing AI's role in predictive healthcare.

Niemann-Pick Disease (NPD) is a well-known entity among the rare causes of lysosomal storage disorders (LSD) and constitutes a significant public health burden globally. The incidence of NPD is 1 in 250,000 individuals with a high prevalence in Ashkenazi Jewish descent, affecting 1 in 40,000 individuals. We report a novel and hitherto unreported. Here we report a case of NPD in a 6 months old male child presented to our hospital with unexplained hepatosplenomegaly with cherry red spots on fundoscopy and with history of death of previous two siblings. The diagnosis of NPD was proven by whole exome sequencing (WES) with identification of novel mutation, homozygote missense variant c.500G>C in exon 2 of sphingomyelin phosphodiesterase 1 (SMPD1) gene that results in the amino acid substitution pCys167Ser. The patient was kept under management of multidisciplinary team. Age of presentation, hepatosplenomegaly, presence of cherry red spots was typical for NPD type A. We report a rare homozygote mutation in the SMPD1 gene.

A 67-year-old white male reported to the clinic with sudden, painless vision loss in the right eye of two hours duration. The patient had several ocular and systemic risk factors for retinal artery occlusion and presented with greatly reduced visual acuity and an afferent pupillary defect in the affected eye. Because of the patient’s extensive macular disease, box-carring was a more prominent feature than the expected cherry red spot or retinal whitening. The patient was diagnosed with an acute central retinal artery occlusion (CRAO) and was sent for an emergent stroke evaluation. The patient went on to develop iris neovascularization within three weeks of initial presentation, demonstrating the importance of early follow-up post-CRAO. This case report highlights the various ocular findings with an acute presentation of CRAO and the potential post-ischemic complications

A 25-year-old man presented with sudden, painless vision loss in his right eye for one day. He had no history of trauma, consanguinity, smoking, headaches, or surgeries. Right eye visual acuity was 1/60, left eye was 6/6, and both eyes had normal intraocular pressure (15 mmHg). The right eye had a relative afferent papillary defect (RAPD), and the fundus showed an altered retinal appearance and a cherry red spot at the macula. Optical coherence tomography showed inner retinal hyperreflectivity with minimal edema. Fluorescein angiography revealed delayed retinal filling (18 seconds), suggestive of central retinal artery occlusion (CRAO). He reported using testosterone injections for hypogonadism for the past two years. Since cardiac, neurological, rheumatological, and hematological workups were normal, testosterone was suspected to be the cause. On a follow-up of two months, his visual acuity improved to 6/60.

Neuronal ceroid lipofuscinosis type 2 (CLN2) results from biallelic pathogenic variants in the TPP1 gene, leading to deficient activity of the lysosomal enzyme tripeptidyl peptidase 1. We report an autopsy case of CLN2 characterized at molecular level. The patient exhibited a spectrum of neurologic symptoms including epilepsy, behavioral alterations, cognitive regression, motor impairment, and visual loss. In fundus exam, a cherry-red spot was observed. She died at 7 years old, autopsy demonstrated severe atrophy of the brain and cerebellum with neuronal loss and gliosis. Neurons were distended by autofluorescent ceroid lipofuscin of 2 types: fine granular deposits and coarse round bodies. In addition, electron microscopy study revealed characteristic curvilinear profiles. After autopsy, a germline molecular test was performed that found the c.1226 G>T variant in a homozygous state. This variant has been referenced in a single undetailed report and is classified as of uncertain significance. Our findings support that cherry-red spot can be present in CLN2 and confirm the pathogenicity of the c.1226 G>T variant. Current management of CLN2 includes enzyme replacement that requires early diagnosis, which can be facilitated by clinical delineation of the disease and appropriate classification and public reporting of TPP1 variants.

A very rare clinical case of a juvenile form of a storage disease mucolipidosis type I (sialidosis) is presented. Ophthalmic features include a bilateral macular cherry-red spot. Bilateral macular optical coherence tomography (OCT) revealed hyper-reflectivity of the ganglion cell layer. CONCLUSION: A cherry-red spot is specific not only for central retinal artery occlusion but also for storage diseases, such as gangliosidoses (Tay-Sachs disease, Sandhoff disease, etc.), mucolipidoses, etc. Ophthalmological examination may be the only key to identify serious systemic diseases, and timely genetic testing might be crucial for a child to determine the adequate therapy. This case was characterized by a typical ophthalmic presentation of sialidosis type I with unclear neurological symptoms suggestive of Tay-Sachs disease. Ophthalmological examination revealed a cherry-red spot with a slow progressing decrease in best-corrected visual acuity (BCVA) which is typical for sialidosis type I but not for Tay-Sachs disease. A neurologist observed the symptoms more characteristic of Tay-Sachs disease than sialidosis type I; they included unsteady gait, ataxia, and dysarthria. There was no myoclonic activity characteristic of sialidosis type I. Thus, genetic testing to identify NEU1 mutations was the only method to objectively examine the patient and determine possible supportive therapy.

Expand genetic screening for atypical Type I sialidosis (ST-1) could address its underdiagnosed in both progressive myoclonic ataxia (PMA) and ataxia patients. To evaluate the potential founder effect of mutation in the population. We enrolled 231 patients with PMA or ataxia from the First Affiliated Hospital of Fujian Medical University. Through Whole Exome Sequencing and Sanger sequencing, we identified the causative gene in patients. Haplotype analysis was employed to explore a potential founder effect of the NEU1 c.544A>G mutation. A total of 31 patients from 23 unrelated families were genetically diagnosed with ST-1. A significant 80.6% of these patients were homozygous for the c.544A>G mutation. We discovered six different NEU1 variants, including two novel mutations: c.951_968del and c.517T>G. The mean age of onset was 18.0 ± 7.1 years. The clinical spectrum of ST-1 featured ataxia and myoclonus as the most common initial symptoms. Over 40% suffered from controlled generalized tonic-clonic seizures. Mobility and independence varied greatly across the cohort. Cherry-red spots were rare, occurring in just 9.5% (2/21) of patients. Brain MRIs were typically unremarkable, except for two patients with unusual findings. EEGs showed diffuse paroxysmal activity in 17 patients. The c.544A>G mutation in NEU1 is a founder variant in Fujian, with a unique haplotype prevalent in East Asians. ST-1 should be suspected in patients with PMA or ataxia in Southeast China, even without macular cherry-red spots and seizures, and the premier test could be a variant screening of the founder variant NEU1 c.544A>G.

Introduction: Gaucher disease is a rare inherited lysosomal storage disorder caused by mutations in the GBA gene, leading to glucocerebrosidase deficiency. This results in the accumulation of glucocerebroside in macrophages, forming "Gaucher cells" that infiltrate various tissues, primarily affecting the liver, spleen, bone marrow, and nervous system. The disease manifests in three types, with Type 1 being the most common and devoid of neurological symptoms. Diagnosis involves enzyme level testing, genetic screening, and imaging, while treatment primarily consists of enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). Case-Report: A one-year-old girl presented with weakness, irritability, and recurrent fever over six months, previously misdiagnosed with malaria and respiratory infections. Physical examination revealed pallor, hepatosplenomegaly, and cherry-red spots on fundoscopy. Laboratory findings indicated anemia, leukocytosis, and severe dyslipidemia, highlighting atypical features for Gaucher disease. Discussion: This case emphasizes the diagnostic challenges in pediatric Gaucher disease, especially with nonspecific symptoms. The combination of cherry-red spots and dyslipidemia suggests a unique variant or severity of the disease, underlining the necessity for heightened awareness among healthcare providers for prompt diagnosis. Conclusion: Gaucher disease should be considered in pediatric patients with unexplained systemic symptoms. Early detection and ERT initiation can significantly improve clinical outcomes. The case illustrates the variability in clinical presentations, emphasizing the need for comprehensive diagnostic evaluation.

Acid sphingomyelinase deficiency (ASMD) is an autosomal recessive lysosomal storage disease (LSD) associated with biallelic pathogenic variants in the sphingomyelin phosphodiesterase 1 (SMPD1) gene. The aim of this study was to provide the 2024 update on chronic visceral and neurovisceral ASMD diagnosed in the infancy/childhood in Polish patients. All the patients diagnosed in the pediatric age (0-18 years) with ASMD, both chronic neurovisceral and visceral type, and then systematically followed up, were enrolled into the study. A total number of 7 patients were enrolled into the study. Four patients were previously reported. Two patients were newly recognized with ASMD - 1 with chronic visceral and 1 with chronic neurovisceral ASMD. Splenomegaly was noted in all the patients while a mild liver enlargement was observed in 4 of 7 patients. All patients presented with decreased high-density lipoprotein cholesterol (HDL-C) and decreased serum 25-hydroxy-vitamin D concentration while almost all (6 of 7) with hypercholesterolemia. Cherry-red spot was observed in 5 of 7 patients, including 1 patient with neurovisceral type. Seven various SMPD1 gene variants were identified and missense variants were the most common types of genetic lesions, comprising 71% of all alleles. In all the screened patients, lyso-sphingomyelin (lyso-SM) in dried blood spot (DBS) was found elevated; however, the greater values were observed for patients with chronic neurovisceral type. Chronic acid sphingomyelinase deficiency (ASMD) is a slowly progressive disease. Pediatric ASMD is characterized by spleno-hepatomegaly, dyslipidemia (with decreased HDL-C as the most characteristic) and infiltrative (interstitial) lung disease. Both visceral and neurovisceral chronic ASMD patients could present with cherry-red spot. Both acid spingomyelinase activity and lyso-spingomyelin concentration in DBS should be regarded as a first-tier screening method into ASMD.